Literature DB >> 628527

Ovulation and pregnancy rates with clomiphene citrate.

G A Gorlitsky, N G Kase, L Speroff.   

Abstract

A review of recent experience with clomiphene citrate at the Yale-New Haven Medical Center yields the following conclusions: 1) Clomiphene citrate administered at high doses (150 mg and 200 mg) is effective in inducing ovulation in women who would otherwise have failed to conceive if treatment were restricted to only lower dosage regimens. 2) Therapy with clomiphene citrate should be initiated with the 50-mg dose. The 100-mg dose should be reserved for those who fail with the lower dose. 3) Children resulting from clomiphene-induced ovulations appear to be developing normally both mentally and physically. Congenital malformations found in children from clomiphene-induced pregnancies are those seen commonly in general obstetric practice resulting in no significant problems for the children. 4) After 3 ovulations with clomiphene citrate approximately 50% of the patients can be expected to conceive. A 50% conception rate after 3 ovulations with clomiphene citrate does not represent a discrepancy between ovulation rates and pregnancy results, for it agrees statistically with the results obtained for the general population.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 628527     DOI: 10.1097/00006250-197803000-00002

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Giants in Obstetrics and Gynecology Series: A profile of Leon Speroff, MD.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2017-07-12       Impact factor: 8.661

2.  Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.

Authors:  Marte Myhre Reigstad; Ritsa Storeng; Tor Åge Myklebust; Nan Birgitte Oldereid; Anne Katerine Omland; Trude Eid Robsahm; Louise Annette Brinton; Siri Vangen; Kari Furu; Inger Kristin Larsen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-20       Impact factor: 4.254

3.  A randomized trial comparing the ovulation induction efficacy of clomiphene citrate and letrozole.

Authors:  Mary Angel; Seetesh Ghose; Mamata Gowda
Journal:  J Nat Sci Biol Med       Date:  2014-07

4.  Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial.

Authors:  Ensieh Sh Tehrani Nejad; Zhila Abediasl; Batool H Rashidi; Elham Azimi Nekoo; Mamak Shariat; Elham Amirchaghmaghi
Journal:  J Assist Reprod Genet       Date:  2008-04-19       Impact factor: 3.412

Review 5.  Adverse effects of fertility drugs.

Authors:  S G Derman; E Y Adashi
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

6.  Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction.

Authors:  Jennifer J Yland; Yu-Han Chiu; Paolo Rinaudo; John Hsu; Miguel A Hernán; Sonia Hernández-Díaz
Journal:  Hum Reprod       Date:  2022-04-01       Impact factor: 6.918

7.  Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation.

Authors:  Mohamed A Bedaiwy; Mahmoud A Abdelaleem; Mostafa Hussein; Noha Mousa; Lisa N Brunengraber; Robert F Casper
Journal:  Reprod Biol Endocrinol       Date:  2011-06-21       Impact factor: 5.211

8.  Comparison of Tamoxifen and Clomiphene Citrate for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Prospective Study.

Authors:  Sangita Sharma; Manisha Choudhary; Vikas Swarankar; Vaibhav Vaishnav
Journal:  J Reprod Infertil       Date:  2021 Oct-Dec

Review 9.  Ovulation induction techniques in women with polycystic ovary syndrome.

Authors:  Andreas A Vyrides; Essam El Mahdi; Konstantinos Giannakou
Journal:  Front Med (Lausanne)       Date:  2022-08-12

10.  Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial.

Authors:  Yan Li; Hongying Kuang; Wenjuan Shen; Hongli Ma; Yuehui Zhang; Elisabet Stener-Victorin; Ernest Hung; Yu Ng; Jianping Liu; Haixue Kuang; Lihui Hou; Xiaoke Wu
Journal:  BMJ Open       Date:  2013-11-25       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.